NL6605692A - - Google Patents

Info

Publication number
NL6605692A
NL6605692A NL6605692A NL6605692A NL6605692A NL 6605692 A NL6605692 A NL 6605692A NL 6605692 A NL6605692 A NL 6605692A NL 6605692 A NL6605692 A NL 6605692A NL 6605692 A NL6605692 A NL 6605692A
Authority
NL
Netherlands
Application number
NL6605692A
Other versions
NL143550B (nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NL6605692A publication Critical patent/NL6605692A/xx
Publication of NL143550B publication Critical patent/NL143550B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL666605692A 1965-04-30 1966-04-28 Werkwijze voor de bereiding van een geneesmiddel met blokkeringseffect ten opzichte van hartstimulantia, dat als actieve verbinding een 1-(gesubstitueerd fenoxy)-2-hydroxy-3-isopropylaminopropaan en/of een zout daarvan bevat, en werkwijze voor de bereiding van de actieve verbinding. NL143550B (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE571165 1965-04-30
US55822666A 1966-06-17 1966-06-17

Publications (2)

Publication Number Publication Date
NL6605692A true NL6605692A (de) 1966-10-31
NL143550B NL143550B (nl) 1974-10-15

Family

ID=26654650

Family Applications (1)

Application Number Title Priority Date Filing Date
NL666605692A NL143550B (nl) 1965-04-30 1966-04-28 Werkwijze voor de bereiding van een geneesmiddel met blokkeringseffect ten opzichte van hartstimulantia, dat als actieve verbinding een 1-(gesubstitueerd fenoxy)-2-hydroxy-3-isopropylaminopropaan en/of een zout daarvan bevat, en werkwijze voor de bereiding van de actieve verbinding.

Country Status (11)

Country Link
US (3) US3466325A (de)
JP (3) JPS50653B1 (de)
BE (1) BE678208A (de)
BR (1) BR6678981D0 (de)
CH (1) CH484053A (de)
DE (1) DE1294955B (de)
FI (2) FI42955B (de)
FR (1) FR5745M (de)
GB (2) GB1140860A (de)
NL (1) NL143550B (de)
NO (1) NO115797B (de)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
WO2007024945A1 (en) 2005-08-25 2007-03-01 Novartis Ag Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2392567A1 (de) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazinderivate und ihre verwendung als lxr-modulatoren
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
EP2810951A2 (de) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP2998314A1 (de) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
EP3241839A1 (de) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3969512A (en) * 1935-11-15 1976-07-13 Boehringer Ingelheim Gmbh N,N'bis-(3-phenoxy-2-hydroxy-propyl)-alkylenediamines and salts thereof
SE354851B (de) * 1970-02-18 1973-03-26 Haessle Ab
US4059622A (en) * 1970-05-27 1977-11-22 Imperial Chemical Industries Limited Alkanolamine derivatives
US3959486A (en) * 1970-05-27 1976-05-25 Imperial Chemical Industries Limited Method for producing β-adrenergic blockage with alkanolamine derivatives
SE386892B (sv) * 1972-07-06 1976-08-23 Haessle Ab Forfarande for framstellning av oxaminoforeningar
US4018825A (en) * 1972-07-27 1977-04-19 Warner-Lambert Company 5-Hydroxy-α-(substituted aminomethyl)-m-xylene-α,α'-diols
US4067904A (en) * 1975-12-19 1978-01-10 Mead Johnson & Company Alkylsulfonylphenoxypropanolamine derivatives
US4119729A (en) * 1975-12-19 1978-10-10 Mead Johnson & Company Alkylsulfonylphenoxypropanolamine therapeutic process
US4243681A (en) * 1977-10-11 1981-01-06 Mead Johnson & Company Alkylthiophenoxypropanolamines and pharmaceutical compositions and uses thereof
EP0013258B1 (de) * 1978-12-29 1982-07-07 Ciba-Geigy Ag Propenylsubstituierte Phenolglycidyläther, Verfahren zu ihrer Herstellung und ihre Verwendung
US4945182A (en) * 1985-12-24 1990-07-31 Merck & Co., Inc. Oculoselective beta-blockers
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
JP2780559B2 (ja) * 1991-01-25 1998-07-30 信越化学工業株式会社 アリル基又はプロペニル基を持つナフタレン誘導体
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (de) 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
ATE192042T1 (de) * 1995-08-16 2000-05-15 Lilly Co Eli Potenzierung von serotonin-wirkstoffresponz
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
US20030087963A1 (en) 2001-09-13 2003-05-08 Senanayake Chris H. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
EP2050441A1 (de) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Verwendung von Beta-Blockern für die Herstellung eines Medikaments zur Behandlung von Hämangiomen
EP2959904A1 (de) 2014-06-27 2015-12-30 Institut De Recerca Contra La Leucemia Josep Carreras Verfahren zur Behandlung, Diagnose und Prognose einer hämatologischen Malignität
FR3030514A1 (fr) * 2014-12-18 2016-06-24 Centre De Coop Int En Rech Agronomique Pour Le Dev (Cirad) Dimeres polyaromatiques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2967201A (en) * 1958-06-02 1961-01-03 Lilly Co Eli Alkylaminoalkyl ethers of phenols
NL300886A (de) * 1962-11-23
NL301580A (de) * 1962-12-11
NL131194C (de) * 1963-07-19
GB1069345A (en) * 1963-07-19 1967-05-17 Ici Ltd New alkanolamine derivatives
DE1493454C3 (de) * 1963-08-26 1980-04-30 C.H. Boehringer Sohn, 6507 Ingelheim 1 -Aryloxy^-hydroxy-S-isopropylaminopropane und deren Salze sowie deren Herstellung und darauf basierende Arzneimittel
CH455834A (de) * 1964-10-14 1968-05-15 Ciba Geigy Verfahren zur Herstellung des neuen 1-Isopropylamino-2-hydroxy-3-(2'-isopropoxy-phenoxy)-propans oder seinen Salzen

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
WO2007024945A1 (en) 2005-08-25 2007-03-01 Novartis Ag Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase
EP2256118A1 (de) 2005-08-25 2010-12-01 Novartis AG Kondensierte Imidazol-Derivative zur Inhibierung der Aromatase
EP2270011A1 (de) 2005-08-25 2011-01-05 Novartis AG Kondensierte Imidazol-Derivative zur Inhibierung der Aromatase
EP2392567A1 (de) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazinderivate und ihre verwendung als lxr-modulatoren
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
EP2998314A1 (de) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
EP2810951A2 (de) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
EP3241839A1 (de) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
EP2923706A1 (de) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Guanylatcyclaseagonisten zur behandlung von hypercholesterinämie
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
EP3708179A1 (de) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulierungen von guanylatcyclase-c-agonisten und verfahren zur verwendung
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds

Also Published As

Publication number Publication date
US3466376A (en) 1969-09-09
NL143550B (nl) 1974-10-15
FR5745M (de) 1968-01-29
NO115797B (de) 1968-12-09
DE1294955B (de) 1969-05-14
FI44392B (de) 1971-08-02
CH484053A (de) 1970-01-15
US3631108A (en) 1971-12-28
BE678208A (de) 1966-09-01
JPS4929182B1 (de) 1974-08-01
BR6678981D0 (pt) 1973-09-18
FI42955B (de) 1970-09-02
GB1140508A (en) 1969-01-22
GB1140860A (en) 1969-01-22
JPS4930819B1 (de) 1974-08-16
JPS50653B1 (de) 1975-01-10
US3466325A (en) 1969-09-09

Similar Documents

Publication Publication Date Title
FI44392B (de)
BE674454A (de)
JPS5317841B1 (de)
JPS437687Y1 (de)
JPS4325271Y1 (de)
JPS452021Y1 (de)
BE674950A (de)
BE674856A (de)
NL6605991A (de)
SE317845B (de)
BE696315A (de)
BE690704A (de)
BE681228A (de)
BE680449A (de)
BE675161A (de)
BE675004A (de)
BE674973A (de)
BE674954A (de)
SE349415B (de)
BE674935A (de)
BE674932A (de)
BE674923A (de)
BE674874A (de)
BE674869A (de)
NL6513352A (de)

Legal Events

Date Code Title Description
NL80 Information provided on patent owner name for an already discontinued patent

Owner name: HASSLE

V4 Discontinued because of reaching the maximum lifetime of a patent